Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinationsStudy design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathwaysTips for optimal coordination between pathology and medical oncologyPresenters: Heather H. Cheng, MD, PhDAssociate ProfessorDepartment of MedicineDivision of Hematology and OncologyAttending PhysicianDepartment of Genitourinary Medical OncologyFred Hutchinson Cancer CenterSeattle, WashingtonColin C. Pritchard, MD, PhDCo-DirectorGenetics and Solid Tumors LaboratoryUniversity of Washington Medical CenterProfessorDepartment of Laboratory Medicine and PathologyUniversity of WashingtonSeattle, WashingtonContent based on an online CME program supported by an independent educational grant from Pfizer, Inc.Link to full program: https://bit.ly/3PFagxb

There are no comments yet.

Please log in to write the first comment.